Special Issue "Human Papillomavirus from Lab to Life: Insights from Molecular Researches"
Deadline for manuscript submissions: closed (31 December 2020).
Interests: HPV, CIN, VIN, AIN, prognosis, genotyping, p16, dual staining, HPV-vaccines
Human Papillomavirus (HPV) affects a significant part of the population worldwide. Although the immunological system is usually able to clear the virus, some infections persist inducing a broad spectrum of cell abnormalities that range from benign proliferations to premalignant lesions at risk of progression to cancer. Approximately 4.5% (640,000 cases) of all new cancers diagnosed yearly worldwide are caused by persistent HPV infection. Despite an impressive amount of information on HPV infection has become available the last years, several gaps still remain regarding HPV disease.
Cervical cancer is one of the most common cancers in women worldwide. HPV infection of cervical epithelium with high-risk (hr-)HPV might result in productive or transforming cervical intraepithelial neoplasia (CIN) lesions, the morphology of which can overlap. On the basis of (epi)genetic changes and aberrations in host-cell genes, early and advanced transforming CIN lesions a risk of progression can be distinguished. The characterization of the transforming infections is a priority in the current landscape of cervical disease, since the identification of HPV positive women at higher risk of premalignancies in the newly introduced HPV-based screening strategies (triage) is fundamental.
Finally, in recent years, we have observed an exponential increase of other HPV-related cancers such as head and neck, anal or vulvar cancers, especially in high-income countries. The natural history and the molecular pathways behind the development of these HPV-associated cancers still remains poorly understood.
In this special issue we look forward promoting and recognizing research on HPV and HPV-associated diseases, focusing on molecular studies. We are calling for manuscripts dealing with biomarkers improving the identification of HPV-associated disease, prognostic markers and strategies of triage for HPV positive women. We aim to provide a broad overview of the ongoing research in the HPV world.
Dr. Marta del Pino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- biomarkers (DNA, mRNA, E6, E7, E4, p16, Ki67, miRNA, methylation, genotyping...)
- HPV vaccines